Tags

Type your tag names separated by a space and hit enter

Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
J Hypertens. 2014 Jun; 32(6):1178-88.JH

Abstract

Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for short-term obesity treatment in conjunction with lifestyle modifications, but is commonly used chronically. Topiramate, approved for treating epilepsy and preventing migraines, also induces weight loss. A single-dose combination of low-dose phentermine and topiramate extended-release was recently approved by the United States Food and Drug Administration as an adjunct to lifestyle intervention for the chronic treatment of overweight/obese adults. This review summarizes and evaluates the cardiovascular risk/benefit profile associated with phentermine and topiramate, individually and in combination. Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk.

Authors+Show Affiliations

aInstitute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany bDepartment of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Denmark cDepartment of Hypertension and Diabetology, Medical University of Gdańsk, Dębinki, Gdańsk, Poland dVIVUS, Inc., Mountain View, California, USA eNational Centre for Cardiovascular Prevention and Outcomes, Institute for Cardiovascular Science, University College London, London, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24621808

Citation

Jordan, Jens, et al. "Cardiovascular Effects of Phentermine and Topiramate: a New Drug Combination for the Treatment of Obesity." Journal of Hypertension, vol. 32, no. 6, 2014, pp. 1178-88.
Jordan J, Astrup A, Engeli S, et al. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014;32(6):1178-88.
Jordan, J., Astrup, A., Engeli, S., Narkiewicz, K., Day, W. W., & Finer, N. (2014). Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. Journal of Hypertension, 32(6), 1178-88. https://doi.org/10.1097/HJH.0000000000000145
Jordan J, et al. Cardiovascular Effects of Phentermine and Topiramate: a New Drug Combination for the Treatment of Obesity. J Hypertens. 2014;32(6):1178-88. PubMed PMID: 24621808.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. AU - Jordan,Jens, AU - Astrup,Arne, AU - Engeli,Stefan, AU - Narkiewicz,Krzysztof, AU - Day,Wesley W, AU - Finer,Nick, PY - 2014/3/14/entrez PY - 2014/3/14/pubmed PY - 2015/2/20/medline SP - 1178 EP - 88 JF - Journal of hypertension JO - J. Hypertens. VL - 32 IS - 6 N2 - Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Phentermine is approved for short-term obesity treatment in conjunction with lifestyle modifications, but is commonly used chronically. Topiramate, approved for treating epilepsy and preventing migraines, also induces weight loss. A single-dose combination of low-dose phentermine and topiramate extended-release was recently approved by the United States Food and Drug Administration as an adjunct to lifestyle intervention for the chronic treatment of overweight/obese adults. This review summarizes and evaluates the cardiovascular risk/benefit profile associated with phentermine and topiramate, individually and in combination. Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk. SN - 1473-5598 UR - https://www.unboundmedicine.com/medline/citation/24621808/Cardiovascular_effects_of_phentermine_and_topiramate:_a_new_drug_combination_for_the_treatment_of_obesity_ L2 - http://dx.doi.org/10.1097/HJH.0000000000000145 DB - PRIME DP - Unbound Medicine ER -